Evidence map›Paper›PMID 38540136›Full record

ArticleBiomedicines2024

Analysis of Primary Chronic Lymphocytic Leukemia Cells' Signaling Pathways.

Josipa Skelin, Maja Matulić, Lidija Milković, Darko Heckel, Jelena Skoko, Kristina Ana Škreb, Biljana Jelić Puškarić, Ika Kardum-Skelin, Lipa Čičin-Šain, Delfa Radić-Krišto and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Josipa SkelinRuđer Bošković Institute, 10000 Zagreb, Croatia.ORCID 0000-0002-7335-8682
Maja MatulićDepartment of Molecular Biology, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-3498-5616
Lidija MilkovićRuđer Bošković Institute, 10000 Zagreb, Croatia.ORCID 0000-0002-4484-039X
Darko HeckelRuđer Bošković Institute, 10000 Zagreb, Croatia.
Jelena SkokoRuđer Bošković Institute, 10000 Zagreb, Croatia.ORCID 0000-0002-9427-3215
Kristina Ana ŠkrebFaculty of Civil Engineering, University of Zagreb, 10000 Zagreb, Croatia.
Biljana Jelić PuškarićDepartment of Clinical Cytology and Cytogenetics, Merkur University Hospital, 10000 Zagreb, Croatia.
Ika Kardum-SkelinSchool of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Lipa Čičin-ŠainRuđer Bošković Institute, 10000 Zagreb, Croatia.ORCID 0000-0002-0222-3174
Delfa Radić-KrištoSchool of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Mariastefania AnticaRuđer Bošković Institute, 10000 Zagreb, Croatia.ORCID 0000-0001-8449-1078
Ruđer Bošković Institute · HRUniversity of Zagreb · HRKlinička bolnica Merkur · HRUniversity of Mostar · BA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder characterized by a specific expansion of mature B-cell clones. We hypothesized that the disease has a heterogeneous clinical outcome that depends on the genes and signaling pathways active in the malignant clone of the individual patient. It was found that several signaling pathways are active in CLL, namely, NOTCH1, the Ikaros family genes, BCL2, and NF-κB, all of which contribute to cell survival and the proliferation of the leukemic clone. Therefore, we analyzed primary CLL cells for the gene and protein expression of NOTCH1, DELTEX1, HES1, and AIOLOS in both peripheral blood lymphocytes (PBLs) and the bone marrow (BM) of patients, as well as the expression of BCL2 and miRNAs to see if they correlate with any of these genes. BCL2 and AIOLOS were highly expressed in all CLL samples as previously described, but we show here for the first time that AIOLOS expression was higher in the PBLs than in the BM. On the other hand, NOTCH1 activation was higher in the BM. In addition, miR-15a, miR-181, and miR-146 were decreased and miR-155 had increased expression in most samples. The activation of the NOTCH pathway in vitro increases the susceptibility of primary CLL cells to apoptosis despite high BCL2 expression.

Indexed as

AIOLOSBCL-2CLLleukemiaNOTCHsurvival

Identifiers

PMID38540136
PMCPMC10968363
OpenAlexW4392162534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.